Authorized purpose: Analyze and visualize functional and dynamic brain MR data and present derived properties and parameters in a clinically useful context for qualified medical personnel; it is not a sole basis for clinical decisions or emergency care.
Clinical role
Post-processing analysis and visualization of functional/dynamic brain MRI with review and export to downstream imaging or navigation systems.
Images and patients
MRI · Brain.
Key limitation
Keep in mind: Not an archive for long-term persistent storage of diagnostic data; not a sole basis for clinical decisions or emergency-care applications; limited to analysis and visualization of human-brain MR data or data derived from it. Qualified users with MR and neuroanatomy training are required.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Analyze and visualize functional and dynamic brain MR data and present derived properties and parameters in a clinically useful context for qualified medical personnel; it is not a sole basis for clinical decisions or emergency care.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain. Input: DICOM functional and dynamic brain MRI from DICOM-compliant devices and modalities, including BOLD task-based fMRI, diffusion MRI, and DSC-perfusion MRI data.
Who uses it?Intended users: Qualified medical personnel, including trained radiological technicians and physicians with training in MR technology and neuroanatomy.
What does the software produce?Output: BOLD voxel-wise task-activation statistics, DTI/SD-derived FA and MD maps, 3D tractography of major white-matter pathways, DSC perfusion maps for blood volume, blood flow, time to peak, mean transit time, and leakage, with browser review and export to DICOM nodes, PACS, neuro-navigation systems, or other DICOM-compliant modalities.
What is its most important limitation?Key limitation: Not an archive for long-term persistent storage of diagnostic data; not a sole basis for clinical decisions or emergency-care applications; limited to analysis and visualization of human-brain MR data or data derived from it. Qualified users with MR and neuroanatomy training are required.
Clinical takeaway. Clinical role: Analyze and visualize functional and dynamic brain MR data and present derived properties and parameters in a clinically useful context for qualified medical personnel; it is not a sole basis for clinical decisions or emergency care.
Evidence takeaway. Evidence from the reviewed source record: FDA K243209 reports non-clinical verification and validation, usability studies, and comparisons of diffusion/tractography and BOLD results with predicate/reference outputs reviewed by internal and external clinical experts. DSC results were compared with reference device K241608 using Lin's concordance correlation coefficient with an acceptance criterion >= 0.8; the packet does not state the achieved CCC value. No numeric sensitivity, specificity, AUC, or disease-detection performance endpoint is reported.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Analyze and visualize functional and dynamic brain MR data and present derived properties and parameters in a clinically useful context for qualified medical personnel; it is not a sole basis for clinical decisions or emergency care.
DICOM functional and dynamic brain MRI from DICOM-compliant devices and modalities, including BOLD task-based fMRI, diffusion MRI, and DSC-perfusion MRI data.
BOLD voxel-wise task-activation statistics, DTI/SD-derived FA and MD maps, 3D tractography of major white-matter pathways, DSC perfusion maps for blood volume, blood flow, time to peak, mean transit time, and leakage, with browser review and export to DICOM nodes, PACS, neuro-navigation systems, or other DICOM-compliant modalities.
Clinical brain-MRI post-processing and visualization; the FDA packet states no patient-population limitation but excludes use as the sole basis in emergency care applications.
Not an archive for long-term persistent storage of diagnostic data; not a sole basis for clinical decisions or emergency-care applications; limited to analysis and visualization of human-brain MR data or data derived from it. Qualified users with MR and neuroanatomy training are required.
FDA K243209 reports non-clinical verification and validation, usability studies, and comparisons of diffusion/tractography and BOLD results with predicate/reference outputs reviewed by internal and external clinical experts. DSC results were compared with reference device K241608 using Lin's concordance correlation coefficient with an acceptance criterion >= 0.8; the packet does not state the achieved CCC value. No numeric sensitivity, specificity, AUC, or disease-detection performance endpoint is reported.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K243209 reports non-clinical verification and validation, usability studies, and comparisons of diffusion/tractography and BOLD results with predicate/reference outputs reviewed by internal and external clinical experts. DSC results were compared with reference device K241608 using Lin's concordance correlation coefficient with an acceptance criterion >= 0.8; the packet does not state the achieved CCC value. No numeric sensitivity, specificity, AUC, or disease-detection performance endpoint is reported.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
nordicMEDiVA regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult and Pediatric
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K243209
IndependenceIndependence not established
K243209
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243209. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM functional and dynamic brain MRI from DICOM-compliant devices and modalities, including BOLD task-based fMRI, diffusion MRI, and DSC-perfusion MRI data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Server-client solution accessed through a browser, with DICOM functionality, APIs, configurable pipelines, and connections to MR modalities, PACS, and surgical-navigation systems. The packet permits local customer-server deployment or cloud/SaaS deployment using a containerized GPU-enabled Linux host; exact interfaces and hosting configuration require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes a server-client solution that can be installed on a local server at the customer's location or in a cloud-based setup, containerized on a GPU-enabled Linux host and accessed via a standard web browser. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "nordicMEDiVA is a server-client solution and can be installed on a local server at the customer's location or in a cloud-based setup." … "software is containerized with Docker technology and operates on a GPU-enabled Linux host.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: BOLD voxel-wise task-activation statistics, DTI/SD-derived FA and MD maps, 3D tractography of major white-matter pathways, DSC perfusion maps for blood volume, blood flow, time to peak, mean transit time, and leakage, with browser review and export to DICOM nodes, PACS, neuro-navigation systems, or other DICOM-compliant modalities.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: BOLD voxel-wise task-activation statistics, DTI/SD-derived FA and MD maps, 3D tractography of major white-matter pathways, DSC perfusion maps for blood volume, blood flow, time to peak, mean transit time, and leakage, with browser review and export to DICOM nodes, PACS, neuro-navigation systems, or other DICOM-compliant modalities.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes a server-client solution that can be installed on a local server at the customer's location or in a cloud-based setup, containerized on a GPU-enabled Linux host and accessed via a standard web browser. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "nordicMEDiVA is a server-client solution and can be installed on a local server at the customer's location or in a cloud-based setup." … "software is containerized with Docker technology and operates on a GPU-enabled Linux host.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Server-client solution accessed through a browser, with DICOM functionality, APIs, configurable pipelines, and connections to MR modalities, PACS, and surgical-navigation systems. The packet permits local customer-server deployment or cloud/SaaS deployment using a containerized GPU-enabled Linux host; exact interfaces and hosting configuration require confirmation.
ACR AI Central provides an exact-submission model card for nordicMEDiVA; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K243209 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.